Psychosis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Psychosis – Drugs In Development, 2024 report and make more profitable business decisions.
Psychosis is a condition that affects the mind and causes a loss of contact with reality. People with psychosis may experience hallucinations (seeing or hearing things that are not there) and delusions (believing things that are not true). Psychosis can be a symptom of various mental disorders, such as schizophrenia, bipolar disorder, or severe depression. It can also be triggered by stress, trauma, or substance use. Psychosis can affect a person’s thoughts, feelings, and behavior, and interfere with their daily functioning. Treatment for psychosis usually involves antipsychotic medication and psychotherapy. Early intervention can improve the outcome and recovery of people with psychosis.
The Psychosis drugs in development market research report provide comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psychosis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Psychosis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 38 molecules, with 37 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Psychosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Psychosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Psychosis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acadia Pharmaceuticals IncAddex Therapeutics Ltd
AgeneBio Inc
Arialys Therapeutics Inc
AstraZeneca Plc
Benuvia Therapeutics Inc
Cennerv Pharma (S) Pte Ltd
Cerevel Therapeutics Holdings Inc
Enterin Inc
Exscientia Plc
Gabather AB
Intra-Cellular Therapies Inc
IRLAB Therapeutics AB
Karuna Therapeutics Inc
Merck & Co Inc
National Institute of Neurological Disorders and Stroke
Neurocrine Biosciences Inc
NW PharmaTech Ltd
Oryzon Genomics SA
Phytecs
Reviva Pharmaceuticals Inc
Sage Therapeutics Inc
Sapient Therapeutics Ltd
Sosei Group Corp
Sumitomo Pharma America Inc
Sun Pharmaceutical Industries Ltd
Suven Life Sciences Ltd
SyneuRx International (Taiwan) Corp
Vanda Pharmaceuticals Inc
Wuhan Docan Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Psychosis reports